SEATTLE — The phase 2 PAVIA trial investigating Duravyu, previously known as EYP-1901, for the treatment of nonproliferative diabetic retinopathy did not meet its primary endpoint, according to a press release from EyePoint Pharmaceuticals.
“Although the phase 2 PAVIA clinical trial did not meet the prespecified primary endpoint of improvement of at least two Diabetic Retinopathy Severity Scale (DRSS) levels at week 36 after Duravyu injection, Duravyu continues to be well tolerated with no drug-related serious adverse events and appears to reduce rates of NPDR progression at 9 months,”